EMBI News and Press, Emerald Bioscience Inc From 08/04/20

Long Beach, CA, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald”), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to address global medical indications, today announced that it has raised approximately $7....

Emerald Bioscience ( OTCQB:EMBI -25.6% )   priced its registered offering of 116.7M units consisting of one share and one warrant to purchase one share at a purchase price of $0.06/unit; gross proceeds expected ~$7M. More news on: Emerald Bioscience Inc., Healthcare stocks news, ,...

Long Beach, CA, July 31, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald”), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to address global medical indications, today announced that it has priced a registered offe...

Bio-engineered analog of CBD (CBDVHS) exhibited highly significant potency when compared to CBD in lowering biomarkers associated with inflammation and fibrosis in a validated human tissue model of ocular disease Contrary to historical studies of CBD, CBDVHS was not associated with an ...

Long Beach, Calif., June 02, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, today announced that the company’s proprietary...

The Alliance is a government-industry consortium that is a leading voice on biosecurity issues in the United States Long Beach, Calif., April 08, 2020 (GLOBE NEWSWIRE) --   Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to ...

Long Beach, California, March 09, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“EMBI”), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, today announced that its...

Long Beach, CA, Jan. 30, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, today announced that Dr. Brian Murph...

Company prepares to enter the clinic in 2020 to test NB1111 (THCVHS) in glaucoma Preclinical formulation testing proprietary analog of CBD examining the utility of CBDVHS in the eye, brain, and liver First patents have been issued for CBDVHS in pursuit of a global patent footpr...

Long Beach, Calif., Jan. 09, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, today announced that Dr. Brian Murp...